Comparative Pharmacology
Head-to-head clinical analysis: LISINOPRIL AND HYDROCHLOROTHIAZIDE versus MAVIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LISINOPRIL AND HYDROCHLOROTHIAZIDE versus MAVIK.
LISINOPRIL AND HYDROCHLOROTHIAZIDE vs MAVIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lisinopril is an ACE inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing diuresis and lowering blood pressure.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and reduced cardiac workload.
Initial dose: 10 mg/12.5 mg orally once daily. Titrate based on blood pressure response; maximum 40 mg/25 mg per day.
Oral, 1-4 mg once daily for hypertension; 2-4 mg once daily for heart failure.
None Documented
None Documented
Lisinopril: terminal half-life 12 hours, effective half-life ~30 hours due to prolonged ACE inhibition. Hydrochlorothiazide: terminal half-life 5.6-14.8 hours (mean 9.6 hours) in patients with normal renal function.
Trandolaprilat: terminal half-life ~24 hours (range 15–35 hours) for once-daily dosing; effective half-life ~6–10 hours at steady state.
Lisinopril: primarily renal (100% unchanged in urine). Hydrochlorothiazide: renal (≥95% unchanged via tubular secretion).
Renal: trandolapril ~33% (as trandolaprilat and metabolites), trandolaprilat ~33% (as unchanged and metabolites); biliary/fecal: ~66% of total radioactivity.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor